MRNA Moderna Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MRNA

Price (delayed)

$122.11

Market cap

$46.8B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$15.66

Enterprise value

$45.96B

Moderna is an American, Cambridge, Massachusetts-based biotechnology company focused on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA . The Moderna technology platform is to insert ...

Highlights
The quick ratio has grown by 27% YoY and by 16% from the previous quarter
MRNA's gross profit has plunged by 88% YoY and by 46% from the previous quarter
The gross margin has plunged by 66% YoY and by 29% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.modernatx.com/
Peers: RGLS MRK NVS JNJ

Key stats

What are the main financial stats of MRNA
Market
Shares outstanding
383.24M
Market cap
$46.8B
Enterprise value
$45.96B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.64
Price to sales (P/S)
9.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.92
Earnings
Revenue
$5.15B
EBIT
-$4.8B
EBITDA
-$4.22B
Free cash flow
-$3.67B
Per share
EPS
-$15.66
Free cash flow per share
-$9.61
Book value per share
$33.55
Revenue per share
$13.49
TBVPS
$43.79
Balance sheet
Total assets
$16.73B
Total liabilities
$3.91B
Debt
$1.21B
Equity
$12.82B
Working capital
$7.22B
Liquidity
Debt to equity
0.09
Current ratio
4.03
Quick ratio
3.64
Net debt/EBITDA
0.2
Margins
EBITDA margin
-82%
Gross margin
22.4%
Net margin
-115.8%
Operating margin
-99.7%
Efficiency
Return on assets
-31.2%
Return on equity
-41.8%
Return on invested capital
-34%
Return on capital employed
-33.5%
Return on sales
-93.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MRNA stock price

How has the Moderna stock price performed over time
Intraday
1.42%
1 week
0.8%
1 month
-0.28%
1 year
1.21%
YTD
22.79%
QTD
2.83%

Financial performance

How have Moderna's revenue and profit performed over time
Revenue
$5.15B
Gross profit
$1.16B
Operating income
-$5.14B
Net income
-$5.97B
Gross margin
22.4%
Net margin
-115.8%
MRNA's gross profit has plunged by 88% YoY and by 46% from the previous quarter
The net margin has dropped by 68% since the previous quarter
The gross margin has plunged by 66% YoY and by 29% from the previous quarter
MRNA's revenue has dropped by 66% year-on-year and by 25% since the previous quarter

Growth

What is Moderna's growth rate over time

Valuation

What is Moderna stock price valuation
MRNA P/E details
P/E
N/A
P/B
3.64
P/S
9.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.92
The company's EPS fell by 27% QoQ
MRNA's P/B is 47% below its 5-year quarterly average of 6.8 but 24% above its last 4 quarters average of 2.9
The equity is down by 32% YoY and by 7% QoQ
The stock's P/S is 80% below its 5-year quarterly average of 45.2 but 62% above its last 4 quarters average of 5.5
MRNA's revenue has dropped by 66% year-on-year and by 25% since the previous quarter

Efficiency

How efficient is Moderna business performance
The company's return on sales has shrunk by 62% QoQ
MRNA's return on equity is down by 40% since the previous quarter
Moderna's ROA has decreased by 39% from the previous quarter
The ROIC has contracted by 32% from the previous quarter

Dividends

What is MRNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRNA.

Financial health

How did Moderna financials performed over time
Moderna's total assets has decreased by 31% YoY and by 9% from the previous quarter
The quick ratio has grown by 27% YoY and by 16% from the previous quarter
The debt is 91% smaller than the equity
The company's debt to equity has surged by 80% YoY
The equity is down by 32% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.